Jupiter Neurosciences, Inc. is a clinical-stage research and development pharmaceutical company. The Company has developed a resveratrol platform product targeting treatment of neuro-inflammation. Its product, JOTROL, has many potential indications of use for rare diseases, which of it primarily is targeting Mucopolysaccharidoses Type 1, Friedreich's Ataxia, and Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes (MELAS). In the larger disease areas, the Company is primarily targeting Parkinson's Disease and Mild Cognitive Impairment/early Alzheimer’s disease. The Company has designated the different indications with project numbers, JNS101 - JNS115. JOTROL is a micellar non-aqueous solution of resveratrol delivered in a soft gel capsule. Each capsule includes 100 milligrams (mg) of resveratrol. It has a worldwide license, from Aquanova AG, the patent holder of micellar technologies, to develop, manufacture, distribute and sell JOTROL.
Código da empresaJUNS
Nome da EmpresaJupiter Neurosciences Inc
Data de listagemDec 03, 2024
Fundado em2016
CEOMr. Christer Rosen
Número de funcionários4
Tipo de títulosOrdinary Share
Fim do ano fiscalDec 03
Endereço1001 North US HWY 1, Suite 504
CidadePALM BEACH GARDENS
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal33477
Telefone15614066154
Sitehttps://jupiterneurosciences.com/
Código da empresaJUNS
Data de listagemDec 03, 2024
Fundado em2016
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.

Sem dados